As 2025 ends, delve into some biotech feel-good stories where the right treatment meets the right patient, almost feeling ...

As 2025 comes to an end, it’s a good moment to take a look at what happened this year in biotech. Unlike years defined by one big breakthrough, 2025 felt more like a phase shift, where many trends ...

For this year’s ‘biotechs to watch’ selection, each Labiotech journalist picked five companies they believe will be worth following in 2026. Some earned their spot after clear momentum in 2025, while ...

Home to excellent research institutions, a thriving life sciences community, a strong collaborative culture, and a strategic location at the heart of Europe, Ghent is now investing in cutting-edge ...

Over the past few years, using artificial intelligence (AI) in drug discovery has stopped being a novelty; instead, it has become part of the standard toolkit across many early-stage programs.